心力衰竭中的代谢-表观遗传相互作用:当前的理解和未来的方向
1Imperial College London, Department of Life Sciences, London, UK.
Biochemical and biophysical research communications
|September 10, 2025
概括
心力衰竭涉及代谢和表观遗传的变化. 这篇评论探讨了它们的交叉对话,揭示了新陈代谢转变如何影响表观遗传学和相反,为心力衰竭提供了新的治疗点.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 心力衰竭是一个全球性健康问题,其原因复杂.
- 已知代谢和表观遗传失调是导致心力衰竭的因素.
- 心力衰竭中代谢和表观遗传变化之间的相互作用尚未得到充分理解.
研究的目的:
- 综合审查心力衰竭中代谢和表观遗传失调之间的相互作用.
- 探索代谢变化如何影响表观遗传修饰.
- 研究表观遗传变化如何影响心力衰竭中的代谢过程.
主要方法:
- 对心力衰竭中的代谢和表观遗传因素研究的文献综述.
- 分析连接新陈代谢和表观遗传学的生物化学途径.
- 整合发现,以创建代谢-表观遗传交叉的框架.
主要成果:
- 代谢变化 (例如,脂肪酸氧化受损,线粒体功能障碍) 通过乙-CoA和NAD+等代谢物改变表观遗传场景.
- 表观遗传失调 (例如,DNA甲基化,基因素乙化) 通过抑制关键基因,导致代谢问题.
- 这种交叉声会在心力衰竭病理生理学中产生一种不适应的循环.
结论:
- 了解代谢-表观遗传交叉对理解心力衰竭至关重要.
- 本综述提供了这些相互连接的途径的综合框架.
- 在这些网络中识别治疗点对治疗心力衰竭具有前景.
相关概念视频
Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure II: Pathophysiology
752
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
752
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Heart Failure I: Introduction
711
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
711
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
943
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
943
Cardiomyopathy V: Interprofessional Care
343
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
343


